JYJunliang Yuan

Junliang Yuan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Junliang Yuan has a total of 207 co-authors. Here are the top co-authors by number of shared publications:

  • Chaobo Bai

    Department of Neurology, Peking University Sixth Hospital, Peking University Institute of Mental Health, Beijing, China

    11 shared publications
  • Danhua Zhao

    Department of Neurology, Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Peking University, Beijing, China

    9 shared publications
  • Yuan Li

    Department of Neurology, Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, People’s Republic of China

    9 shared publications
  • Qi Wang

    Department of Neurology, Peking University Sixth Hospital, Peking University Institute of Mental Health, Beijing, China

    8 shared publications
  • Baoyu Chen

    Department of Neurology, Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Peking University, Beijing, China

    7 shared publications
  • Jing Chen

    Department of Neurology, Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Peking University, Beijing, China

    7 shared publications

Latest Publications

  • Open Access

    Editorial: Biomarkers for early detection and progression of Parkinson's disease: integrating genomic, proteomic, imaging, and clinical advances

    by Wen Ma, Junliang Yuan

    Research staging (Simuni et al., 2024). However, identifying pathology, predicting disability, and monitoring treatment response represent distinct clinical objectives. This research topic brings together genetic, molecular, imaging, and clinical investigations to examine how complementary measurements might support earlier detection and more informative characterization of PD. Its contributions also expose the distance between a promising relationship and a clinically useful biomarker.Genetic studies emphasize that biological interpretation depends on population context. Arias-Carrión et al. synthesize evidence from Mexican populations, highlighting established PD-related pathways alongside methodological heterogeneity and limited ancestry-aware analyses.Their findings reinforce the importance of the broader multi-ancestry research agenda (Kim et al., 2024). Soraya et al. combine preliminary Indonesian family observations with a meta-analysis of apolipoprotein E (APOE) ε4 and clinical features. The pooled evidence associates ε4 carriage with modestly earlier onset, without significant differences in Hoehn-Yahr stage or Mini-Mental State Examination scores. These endpoint-specific findings caution against treating a genetic association with onset as evidence of accelerated progression; the very small local sample also precludes population-level inference. The need to distinguish diagnostic discrimination from biological interpretation is particularly clear in the study by Li, Luo, and Bai. Plasma α-synuclein distinguished PD from healthy controls with an AUC of 0.976, but this estimate came from a relatively small cohort of 52 patients and 62 healthy controls. Performance against healthy individuals does not establish differential diagnostic value in patients with atypical or secondary parkinsonism. Moreover, nominal associations between quantitative susceptibility mapping (QSM) measures and clinical features did not survive age adjustment and correction for multiple comparisons, illustrating the importance of confounding control. Peripheral α-synuclein concentrations were not directly associated with regional susceptibility. These results leave the complementary value of the two measurements unresolved.Total plasma α-synuclein should also be distinguished from seed amplification measures of pathological aggregation. Replication with standardized sample handling and clinically relevant disease controls is needed before diagnostic performance can be generalized. and meta-analysis of brain-derived neurotrophic factor (BDNF). Blood BDNF was lower in PD overall, but the difference was significant in serum, not plasma, and heterogeneity was substantial.Only three CSF studies were available, with no significant pooled difference and unstable results.Lower serum BDNF was also associated with cognitive impairment, supporting further phenotype-specific investigation. However, platelet release during sample processing and incompletely assessed medication effects complicate interpretation. These findings caution against treating peripheral BDNF as a direct measure of central neurotrophic activity or an established progression marker.Accessible peripheral measurements offer another route to detailed phenotyping. Dong et al. Even if an intervention changes both microbial profiles and symptoms, mediation analyses and temporal evidence will be needed to determine whether microbial changes contribute to improvement.Across these contributions, the key translational question is which clinical decisions a biomarker could help inform. Future studies should prespecify whether the intended use is prodromal identification, differential diagnosis, prognosis, or response monitoring. Longitudinal cohorts need repeated measurements and outcomes meaningful to patients, including cognitive decline, falls, and loss of independence. Models should be evaluated in independent settings, across ancestry groups and disease stages, with attention to calibration, confounding, and added value over clinical assessment. Multimodal integration is justified when it improves those decisions sufficiently to offset additional cost and burden. The contribution of this Research Topic is to identify promising biological and clinical connections while clarifying the validation needed to make them useful in PD research and care.

  • Open Access

    Resting-State EEG Characteristics of Tardive Dyskinesia: Spectral and Network Connectivity Insights

    by Linyuan Yan, Bingyan Xie, Yi Sun, Miao Zheng, JinJin Wang, Yuan Li, Jing Chen, Shiyu Zhou, Xin Yu, Junliang Yuan

    Background and Hypothesis: Tardive dyskinesia (TD) is an often irreversible movement disorder, mostly resulting from exposure to dopamine receptor antagonists. The electrophysiological characteristics of TD remain poorly understood. Resting-state electroencephalography (EEG) may help characterize frequency-specific cortical oscillatory and network alterations related to TD. We hypothesized that TD-related neurophysiological alterations may be reflected in cortical spectral power, hemispheric asymmetry, and large-scale functional connectivity. Study Design: Resting-state EEG was recorded with a 32-channel system in 67 participants: 20 patients with TD, 25 patients without TD, and 22 healthy controls. Analyses focused on spectral power, hemispheric asymmetry, and functional connectivity measured using phase-lag index. Electrode-level spectral power analyses were corrected using the false discovery rate, and network-level connectivity differences were assessed using network-based statistics. Subgroup clinical association analyses within the TD group were considered exploratory. Study Results: Compared with healthy controls, both TD and Non-TD patients showed increased theta relative power at central electrodes, including C4 and Cz, with group effects surviving false discovery rate correction. Cluster-based topographic analyses showed increased gamma2-gamma3 power over frontoparietal regions in TD patients and increased broadband gamma power over frontal-central regions in Non-TD patients relative to healthy controls. Within the TD subgroup, exploratory analyses showed nominal associations between hemispheric asymmetry indices and rapid medication withdrawal or duration of motor disorder, although these associations did not survive false discovery rate correction. Functional connectivity analyses identified frequency-specific network alterations, including reduced phase-locking value in the theta frequency band and reduced phase-lag index connectivity across alpha1, beta, and gamma frequency bands in TD-related comparisons. Conclusion: TD patients showed altered resting-state cortical oscillations and frequency-specific connectivity changes involving central, frontoparietal, and temporo-occipital networks. These findings provide preliminary electrophysiological evidence for cortical network involvement in TD and may inform future mechanistic studies. Given the modest sample size and exploratory nature of subgroup analyses, the findings should be interpreted cautiously and validated in larger longitudinal cohorts.


  • Open Access

    Physical frailty, depressive symptoms, and cognitive decline before and after Parkinson’s disease diagnosis: a population-based prospective study of the SHARE and ELSA cohorts

    by Ziyang Ren, Zuliyaer Talifu, Xinyue Lin, Yuchun Sun, Yihao Zhao, Jing Chen, Danhua Zhao, Jufen Liu, Junliang Yuan, Xiaoying Zheng

    Parkinson's disease (PD) is increasingly common, yet its multidomain prodromal evolution remains incompletely characterised. Among 49,039 participants aged ≥50 years from the Survey of Health, Ageing and Retirement in Europe (SHARE), 624 incident PD cases occurred for up to 9 years. Compared with non-frailty, physical frailty was associated with a higher PD risk (HR = 2.31, 95% CI: 1.82-2.94); corresponding HRs were 1.95 (95% CI: 1.55-2.46) for severe depressive symptoms and 1.66 (95% CI: 1.34-2.06) for severe cognitive impairment. Risks were greatest when deficits co-occurred across all three domains (HR = 3.20, 95% CI: 2.42-4.24). Short-term worsening in multidomain health was associated with higher PD risk, whereas recovery to a more favourable state was associated with lower risk. The joint trajectory characterised by high physical frailty, high depressive symptoms, and low cognitive performance showed the highest risk of PD (HR = 4.21, 95% CI: 2.36-7.51). PD was also associated with progression to less favourable health states and reduced recovery, while future PD cases in both the SHARE and English Longitudinal Study of Ageing (ELSA) showed faster pre-diagnostic deterioration, particularly in depressive symptoms and verbal fluency, with abrupt worsening around diagnosis. These findings support repeated multidomain monitoring to improve PD risk stratification in older adults.


  • Open Access

    Association Between Cardiovascular Risk Factors and the Progression of Motor and Non-Motor Symptoms in Parkinson’s Disease: A Five-Year Cohort Study

    by Junyi Chen, Jing Chen, Zhe Zhao, Danhua Zhao, Baoyu Chen, Qi Wang, Yuan Li, Chaobo Bai, Xintong Guo, Jinjin Wang, et al.

    Objective: To investigate the relationship between cardiovascular risk factors and the progression of motor and non-motor symptoms in Parkinson’s disease (PD). Methods: We used data from the Parkinson’s Progression Markers Initiative (PPMI) cohort with a follow-up duration of >5 years. Baseline assessments included genetic analysis, brain MRI, cardiovascular risk factors, and overall cardiovascular disease (CVD) risk. Motor symptoms and non-motor symptoms of PD were evaluated using the Movement Disorders Society revised Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and sub-scores, Hoehn–Yahr stage, and Montreal Cognitive Assessment (MoCA). Statistical analyses comprised univariate and multivariate linear regression and stratified analysis. Results: A total of 169 newly diagnosed PD patients and 78 healthy controls (HCs) were included. At baseline, no significant differences in cardiovascular risk factors or overall CVD risk were observed between PD patients and HCs. Hypertension (β = 6.748, p = 0.040) and hyperlipidemia (β = 8.316, p = 0.005) were associated with faster motor progression. ApoE genotype was correlated with motor progression (β = 7.593, p = 0.007). PD patients with a moderate-to-low CVD risk (p = 0.048) and lower MDS-UPDRS Part I total scores (7.0 [IQR, 6.25] vs. 9.0 [IQR, 7.0], p = 0.039) at last follow-up compared to high-CVD-risk (≥20%) patients. Overall CVD risk was negatively correlated with total MoCA score at last follow-up (β = −0.208, p< 0.001). Conclusions: Cardiovascular risk factors accelerate the progression of motor and non-motor symptoms in PD, suggesting that management of modifiable CVD risk factors may represent a promising target to delay the progression of PD.

  • Open Access

    Associations between sleep disturbance and cerebrospinal fluid Aβ, and shared proteomic signatures in Alzheimer's disease

    by Tianbai Li, Meichen Liu, Peng Zhang, Song Li, Tao Qiu, Xinhui Qiu, Bo Sun, Huaibin Cai, Cong Liu, Junliang Yuan, et al.

    INTRODUCTION: Sleep disturbance is increasingly recognized as a risk factor for Alzheimer's disease (AD), but longitudinal clinical evidence linking sleep behaviors to cerebrospinal fluid (CSF) amyloid beta (Aβ) dynamics and related proteomic signatures remains limited. METHODS: We analyzed 1205 participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) to examine associations between sleep disturbance, CSF Aβ42 level, and cognition. To prioritize molecular candidates associated with these phenotypes, we integrated CSF proteomics with weighted gene co‐expression network analysis (WGCNA) and two‐sample Mendelian randomization (MR). RESULTS: Baseline sleep disturbance was associated with a faster rate of longitudinal CSF Aβ42 decline. WGCNA identified a protein module associated with sleep disturbance and Aβ42, within which MR supported effects of sleep disturbance on multiple proteins. Among these, interferon γ‐inducible protein 16 is a candidate link between sleep disturbance and Aβ pathology. DISCUSSION: Our findings suggest that sleep disturbance accelerates Aβ pathology, and implicate IFI16‐related pathway as a link between disrupted sleep and AD progression.


  • Open Access

    Gut microbiota-dependent 24-hydroxycholesterol metabolism contributes to capsaicin-induced amelioration of Alzheimer’s disease-like pathology in mice

    by Yawen Li, Hui Wang, Dongyuan Zhang, Shiqi Wang, Zheng Li, Jingjie Li, Shentao Tai, Dandan Tong, Bifeng Wang, Dingbing Lu, et al.

    Dietary capsaicin intake appears to affect the pathogenesis of Alzheimer’s disease (AD), while the underlying mechanisms remain unclear. Here, we found in human cohorts that moderate-to-high level of dietary capsaicin intake was associated with improved cognitive performance. Similarly, long-term oral capsaicin administration in male 5×FAD mice ameliorated AD-like pathologies and reshaped gut microbial composition. Gut microbiota transfer from capsaicin-treated mice produced similar effects of capsaicin intake. Moreover, capsaicin elevated the level of host 24(S)-hydroxycholesterol (24-HC), relating to the increase of gut Oscillibacter genus abundance. The 24-HC elevation enhanced microglial phagocytic activity in the brain, and inhibited proinflammatory factors production via liver x receptor β (LXRβ)-mediated transcriptional regulation. Finally, we observed elevation of 24-HC in plasma in AD patients with higher level of dietary capsaicin intake, which correlated with cognitive scores and plasma Aβ and p-tau biomarkers. These findings suggest the potential of capsaicin or capsaicin-rich diets in the prevention or treatment of AD and related diseases.


  • Open Access

    The association between depression, anxiety, sleep disturbances and dementia: a prospective cohort study of 350,186 adults

    by Chaobo Bai, Tian Feng, Ninghao Huang, Qi Wang, Jing Chen, Danhua Zhao, Baoyu Chen, Yuan Li, Junyi Chen, Xintong Guo, et al.

    Depression, anxiety, and sleep disturbances are modifiable neuropsychiatric conditions, yet their trajectories and combined impact on dementia subtypes rem

  • α-Synuclein Deletion Leads to Hyposmia: due to Defective Autophagy Induced by Abnormal PI3K/mTOR Signaling Pathway in Olfactory Bulb

    by Yuqing Shi, Huizhi Wang, Jing Chen, Jing Ren, Xiaohong Sun, Mingqin Qu, Tongfei Zhao, Chunlei Han, Junliang Yuan, Fangang Meng, et al.

    α-Synuclein has been the center of focus in understanding synucleinopathies such as Parkinson’s disease, amyotrophic lateral sclerosis, multiple system atrophy, dementia with Lewy bodies, for decades. Most researches focus on its pathology. However, its physiological function remains elusive, especially in olfactory system, one of the original sites to find α-synuclein accumulation in Parkinson’s disease. In the present study, α-synuclein knockout (KO) mice were employed to study its physiological function. KO mice exhibited olfaction impairment with cell apoptosis in olfactory bulb. To identify molecules underlying olfactory dysfunction, we employed proteomics based on isobaric tags for relative and absolute quantification (iTRAQ). 188 differentially expressed proteins were identified between KO mice and its littermate control of wildtype mice. Bioinformatic analysis highlighted Phosphatidyl-inositol-3-kinase (PI3K) pathway. Hence, we examined its activation and found that both PI3K and its downstream, protein kinase B(AKT) is hyperactivated with α-synuclein deficiency. Mammalian target of Rapamycin (mTOR), a switch of autophagy, was activated followed by uncoordinated 51-like kinase 1, the autophagy initiator, inhibition. The specific substrate of autophagy, P62 was accumulated, indicating that autophagy was blocked. This blockade of autophagy led to Caspase 8 mediated apoptosis characterized by an increased ratio of B-cell lymphoma-2 (BCL-2)-associated X protein (BAX) to BCL-2 (BAX/BCL-2), reduced mitochondrial complex I activity, and decreased mitochondrial membrane potential. To summarize, α-synuclein played roles in maintaining the normal structure and function of olfactory system. α-Synuclein deletion induced Caspase 8 mediated apoptosis due to the defective autophagy by PI3K/mTOR hyperactivation.


  • RetSat Knockout Mitigates Hypoxia‐Induced Microglial Activation by Enhancing Lipid Droplets Degradation

    by Wenyu Hu, Shuoshuo Li, Wenjun Shi, Ping Zhang, Xue Zhang, Ying Liu, Xin Zhou, Peng Shi, Junliang Yuan, Zengqiang Yuan, et al.

    Exposure to hypoxic environments leads to neurological dysfunction, with recent studies implicating microglia‐derived neuroinflammation involved in hypoxia‐induced neuronal impairment. However, the underlying pathological mechanisms remain largely unclear. Lipid‐droplet‐accumulating microglia (LDAM) have been linked to age‐related and genetic forms of neurodegeneration, prompting the investigation of their role in hypoxia‐induced neuronal impairment. In this study, we observed that hypoxia induced lipid droplets accumulation in microglia, accompanied by increased levels of RETSAT, an enzyme involved in lipid metabolism regulation. Conditional knockout of RETSAT in microglia decreased lipid droplets accumulation and alleviates hypoxia‐induced microglial‐derived neuroinflammation and oxidative stress, both in vitro and in vivo. Our biological studies indicate that the beneficial effects of RETSAT knockout on lipid droplets degradation are primarily mediated through enhanced activity of hormone‐sensitive lipase (HSL). Furthermore, we found that the hypoxic adaptation‐related RETSAT mutation Q247R promotes microglia lipolysis under hypoxic conditions. These findings suggest that RetSat is a potential therapeutic target for the prevention and treatment of hypoxia‐induced microglial activation.


  • Open Access

    White matter neural substrates in alcohol dependence with genetic risk and their role in pathological reward process

    by Fei Wu, Guowei Wu, Ping Dong, Jiahui Deng, Xuejiao Gao, Peng Li, Junliang Yuan, Hongqiang Sun

    Studies have revealed significant evidence of white matter (WM) microstructural and network connectome abnormalities in alcohol use disorder (AUD). However, the neuroimaging characteristics of alcohol dependence (AD) patients with a family history of AUD and the role of these changes in pathological craving remain unclear. Investigating the heritability of AUD is crucial for identifying genetic predispositions and informing targeted prevention strategies. The study recruited 51 patients for AD, 21 patients with a family history positive (FHP), 30 patients with a family history negative (FHN), and 25 healthy controls (HC). We compared fractional anisotropy (FA) and mean diffusivity (MD) of striatal circuits and topological properties of the reward system between the three groups. Then, covariates of alcohol use characteristics (duration and severity of AD) were controlled between FHP and FHN. We found abnormal topological properties of hippocampus in AD with FHP compared to HC. After controlling for covariates, there were still disruptions of topology organization in FHP compared to FHN, such as lower nodal betweenness, nodal degree and higher shortest path of right hippocampus. The nodal topological properties of right hippocampus were significantly correlated with self-reported craving in AD. Our findings provide robust evidence for WM neural abnormalities in AD with high genetic risk. We also found the disrupted topological properties of the right hippocampus associated with craving level.